Please login to the form below

Not currently logged in
Email:
Password:

rifaximin

This page shows the latest rifaximin news and features for those working in and with pharma, biotech and healthcare.

Valeant's proposed sale of Salix to Takeda 'in jeopardy'

Valeant's proposed sale of Salix to Takeda 'in jeopardy'

Now, the Canadian company has decided to build up Salix' salesforce to push its flagship brand – Xifaxan (rifaximin) for diarrhoea caused by irritable bowel syndrome – which has been tipped by some

Latest news

  • FDA approves two new IBS medicines FDA approves two new IBS medicines

    The FDA has approved two new treatments for irritable bowel syndrome with diarrhoea (IBS-D) in the form of Actavis' Viberzi (eluxadoline) and Salix' Xifaxan (rifaximin). .

  • Valeant raises offer for Salix; rival Endo bows out Valeant raises offer for Salix; rival Endo bows out

    The Canadian company is banking on the future success of Salix' traveller's diarrhoea and hepatic encephalopathy therapy Xifaxan (rifaximin), which is in the final stages of FDA review for the

  • Endo tries to ride out Valeant with $15.7bn bid for Salix Endo tries to ride out Valeant with $15.7bn bid for Salix

    Salix would give it an entry into the gastrointestinal therapy category, bringing in products such as traveller's diarrhoea and hepatic encephalopathy therapy Xifaxan (rifaximin), as well as other products like

  • Valeant swoops on Salix with $10bn takeover deal Valeant swoops on Salix with $10bn takeover deal

    Adding Salix to the fold will bring in traveller's diarrhoea and hepatic encephalopathy therapy Xifaxan (rifaximin), as well as other products such as diabetes therapy Glumetza (extended-release metformin) that

  • Norgine close to final yes from NICE on Targaxan Norgine close to final yes from NICE on Targaxan

    The drug-pricing watchdog is recommending that Norgine's Targaxan ( rifaximin) be funded as a treatment option for preventing recurrent episodes of hepatic encephalopathy, a brain condition caused by liver failure. ... Rifaximin can prevent these

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2013 Pharma deals during November 2013

    The all-cash transaction is expected to close in Q1 2014. The combined company will market 22 products, including Xifaxan (rifaximin; 2012 sales of $514.5m) and Santarus' therapy Glumetza (metformin)

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics